NeuroVive Pharmaceutical has raised $3.3 million (€2.9 million) from Taiwanese investors to finance early aspects of its Asian expansion. The fundraising moves NeuroVive a step closer to realizing its plan to list its subsidiary on the Taiwan stock exchange.
Biotech upstart Vaxxas raised $20 million in the first close of its B round, cash that'll help the biotech develop a needle-free technology for vaccinations.
LONDON-- High-profile British fund manager Neil Woodford rolled out plans to raise about $300 million for an investment trust that will bet heavily on the U.K.'s struggling biotech sector.
Menlo Park, CA's Armetheon raised a $24.3 million B round to support work on a new oral blood thinner the biotech believes can fill a hole in the blockbuster anticoagulant market.
North Carolina's G1 Therapeutics hauled in $33 million to advance a headline-grabbing approach to cancer treatment, helping the biotech hit the gas in a space otherwise dominated by Big Pharma.
Revolution Medicines is developing technology it believes can do evolution one better, improving on naturally occurring compounds to transform promising but raw molecules into discrete drug candidates. And, with the help of $45 million from Third Rock Ventures, the biotech is first setting its sites on a pedigreed antifungal therapy.
Jim Mellon wants to put his theory that British and European biotechs are undervalued to the test. The famed investor is trying to raise up to £100 million ($150 million) for a new fund dedicated to small biotechs in the United Kingdom and the rest of Europe.
Kees Been has banked the $20 million round needed to move a bold new development program for delaying or preventing Parkinson's toward the clinic. And the veteran biotech CEO at the helm of Lysosomal Therapeutics Inc. is moving forward with a group of high-profile backers in his corner.
A U.S./Japanese hybrid biotech chaired and co-founded by Gregory Verdine, the high-profile Harvard investigator now laboring as CEO of Warp Drive Bio, has gathered together $18 million in a transpacific venture round and set its sights on developing a "revolutionary" new class of nucleic acid drugs based on a potentially breakthrough approach to drug design.
Study startup specialist goBalto is preparing to up its game in Asia. The San Francisco, CA-based software developer outlined the strategy after raising $12 million from new backers, including Japan's Mitsui Global Investment.